Table 2.
Blood analytes at different time points (PP considering compliance), mean (SD) and repeated measures ANOVA statistics
| Parameter | geniVida bone blend (n = 30) | Placebo (n = 28) | p = GBB versus Plc | |||||
|---|---|---|---|---|---|---|---|---|
| BSL | 3 months (V2) | 6 months (V3) | BSL | 3 months (V2) | 6 months (V3) | BSL/V2 | BSL/V3 | |
| BAP (μg/L) | 14.68 (4.64) | 15.17 (4.38) | 15.06 (4.87) | 15.94 (3.96) | 14.52 (3.03) | 14.71 (3.93) | 0.002 | 0.054 |
| Ntx/crt (nM/mM crt) | 40.73 (11.75) | 41.33 (12.15) | 45.23 (14.17) | 44.46 (13.01) | 44.04 (12.54) | 41.46 (12.01) | ns | 0.024 |
| Genistein tot (ng/mL) | 2.1 (9.7) | 96.1 (88.1) | 129.8 (179.7) | 4.8 (14.5) | 1.5 (4.4) | 2.6 (5.6) | <0.001 | <0.0001 |
| 25(OH)D (nM/L) | 74.9 (23.0) | 90.2 (16.5) | 91.1 (17.8) | 76.3 (22.2) | 80.7 (23.1 | 78.1 (18.8) | 0.009 | 0.009 |
| Phylloquinone (nmol/L) | 2.2 (3.1) | 2.6 (2.9) | 2.1 (2.1) | 1.5 (2.2) | 1.6 (1.3) | 1.2 (0.9) | 0.07 | ns |
| EPA (μg/100μL) | 2.87 (1.06) | Not determined | 7.16 (2.86)** | 4.17 (4.28) | Not determined | 4.09 (4.05) | na | 0.003* |
| DHA (μg/100μL) | 7.29 (2.71) | Not determined | 11.17 (4.16)** | 9.35 (5.20) | Not determined | 8.34 (5.59) | na | <0.05* |
BSL Baseline, V2: 3-month visit, V3: 6-month visit, Reference range: BAP: 0–22.4 μg/L, ns nonsignificant, na not applicable, 25(OH)D 25-hydroxyvitamin D3, EPA Eicosapentaenoic acid (C20:5n-3), DHA Docosahexaenoic acid (C22:6n-3)
* Significant at V3 versus placebo
** Significant versus BSL (p < 0.0001)